Chinese chemical inconsistency yields drug 'caveat emptor'

"Most Chinese chemicals are high quality, but poor oversight, weak regulation, and occasional grotesque negligence will likely compromise drug quality," says Roger Bate of the American Enterprise Institute. "There are no simple solutions to this problem; with healthcare costs escalating globally, the idea that we should pay even more for drugs to ensure safety is a tough sell. But at the very least, patients should realize that not all the drugs they take, even allegedly bioequivalent generics, will in fact work perfectly. It really is a case of caveat emptor." Story

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.